COYA · Coya Therapeutics Inc
United States · RS rating 22 · As of 2026-10-14
| Price | 4.18 USD |
|---|---|
| 1-day change | -6.6% |
| RS rating (overall / 1M / 3M / 12M) | 22 / 23 / 34 / 21 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 26 / 12 / 27 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | +12.5% |
| Sales growth Q/Q | +11.1% |
| Distance from 52-week high | +43.2% |
| Market cap (USD) | $101.8M |